Survival analysis and life expectancy of pediatric patients with spinal muscular atrophy in Thailand
Issued Date
2024-06-15
Resource Type
ISSN
24058440
Scopus ID
2-s2.0-85195283625
Journal Title
Heliyon
Volume
10
Issue
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
Heliyon Vol.10 No.11 (2024)
Suggested Citation
Sittiyuno P., Kulsirichawaroj P., Leelahavarong P., Sanmaneechai O. Survival analysis and life expectancy of pediatric patients with spinal muscular atrophy in Thailand. Heliyon Vol.10 No.11 (2024). doi:10.1016/j.heliyon.2024.e32732 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98736
Title
Survival analysis and life expectancy of pediatric patients with spinal muscular atrophy in Thailand
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Survival data for Thai patients with 5q spinal muscular atrophy (SMA), the leading cause of infant mortality worldwide, are lacking. Objective: This study aimed to determine the survival rates and life expectancies of pediatric patients with SMA types 1, 2, and 3. Methods: We conducted a retrospective cohort analysis of genetically confirmed 5q SMA patients aged 0–18 years who were treated between 1999 and 2021 at the pediatric neuromuscular clinic of Siriraj Hospital, Bangkok, Thailand. Mortality data were sourced from the Civil Registration Office. Results: The study included 113 patients: 37 with SMA type 1, 53 with type 2, and 23 with type 3. Life expectancy varied significantly by SMA type: 2.2 years for type 1, 11 years for type 2, and 16.5 years for type 3. The median survival times for SMA type 1 and 2 were 1.9 and 19 years, respectively. In SMA type 2, early onset (<1 year) correlated with a shorter median survival than later onset (≥1 year) (log-rank test P = 0.009). Early onset SMA type 2 had a median survival time of 15.9 years, while 75 % of those with later onset SMA type 2 survived until the age of 19 years. Cox proportional hazards analysis revealed that each month's delay in disease onset reduced the annual mortality risk by 17 % for type 1 patients and by 20 % for type 2 patients. Compared with female patients, male patients with type 2 disease had a 12-fold increased mortality risk. Conclusions: Age at onset is a significant predictor of survival and life expectancy in patients with SMA types 1 and 2. These insights are crucial for genetic counseling and prognostic discussions in clinical settings.